- Poster presentation
- Open Access
Anidulafungin compared with fluconazole therapy in critically ill patients
© BioMed Central Ltd. 2010
- Published: 1 March 2010
- Public Health
- Emergency Medicine
- Retrospective Analysis
- Initial Treatment
The 2009 IDSA Treatment Guidelines for Candidiasis favor an echinocandin for initial treatment of candidemia in patients with severe illness. In a prospective, randomized study anidulafungin resulted in improved global response (GR) and a trend toward improved survival compared with fluconazole .
Retrospective analysis in patients classified as severely ill at study entry: treatment initiated in an ICU (Group 1), APACHE II score ≥15 (Group 2) or presence of severe sepsis (Group 3). Within groups, anidulafungin was compared with fluconazole for GR rate at the end of intravenous therapy and 14-day and 28-day mortality.
In patients with severe illness, anidulafungin was associated with greater GR than fluconazole, significantly so for those with APACHE II score ≥15 or with MOD, supporting the IDSA Guidelines.